Loading clinical trials...
Loading clinical trials...
To investigate the severity of secondary Raynaud's disease-related attacks during the 14 days 2101 dosing period.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Response Pharmaceuticals
NCT02396238 · Scleroderma, Systemic Sclerosis, and more
NCT01090492 · Raynaud's Disease, Peripheral Vascular Disease
NCT02683408 · Raynaud's Disease
NCT02615964 · Raynaud's Disease
NCT00577304 · Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, and more
University des Saarlandes
Homburg
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions